The present study was designed to test the hypothesis that Hcys reduces intracellular nitric oxide concentrations ([NO] i ) and stimulates superoxide (O 2 .-) production in the renal arterial endothelium, thereby resulting in endothelial dysfunction. Using fluorescence microscopic imaging analysis, a calcium ionophore, A23187 (2 µΜ) and bradykinin (2 µM) were found to increase endothelial [NO] i in freshly-dissected lumenopened small renal arteries loaded with DAF-2DA (10 µM). Pre-incubation of the arteries with L-Hcys (20-40 µM) significantly attenuated the increase in endothelial [NO] i .
Hyperhomocysteinemia (hHcys) is recognized as a novel independent risk factor of thrombosis and arteriosclerosis involving coronary, cerebral, and peripheral arteries (3, (8) (9) (10) 30) . Homocysteine (Hcys), a sulfur-containing amino acid, is not present in our regular diet and primarily formed from methionine by demethylation in a variety of tissues or cells, and L-Hcys is an primary active form within the cells. Based on the observations in the patients with an inborn metabolic error homocystinuria and in the animal models with experimental hHcys, Dr. McCully formulated the "homocysteine theory" of atherosclerosis to speculate that deranged Hcys regulation might cause cardiovascular diseases in the general populations (25, 27) . Recently, numerous clinical and epidemiological studies have demonstrated a positive correlation between plasma Hcys levels and cardiovascular diseases. It has been reported that plasma total homocysteine (tHcys) levels increased in many patients with essential hypertension, stroke, atherosclerosis or end-stage renal disease (ESRD) (2, (8) (9) (10) 15) . hHcys is also considered as a new crucial element in the pathogenesis of uremic cardiovascular complications (12) .
Despite intensive clinical studies demonstrating the association of hHcys and cardiovascular diseases, the mechanisms by which hHcys produces cardiovascular dysfunction, atherosclerosis and end-stage organ damages have not been fully elucidated.
There is accumulating evidence indicating that endothelial injury or dysfunction is one of the important early pathological changes in the development of atherothrombotic vascular disease and some other end-stage organ damage (2, (8) (9) (10) 15) . In this regard, animals with chronic hHcys exhibited an impaired endothelium-dependent vasodilator response (34). It has been suggested that homocysteine produces endothelial dysfunction by decreasing NO production (23, 36) . However, this conclusion was drawn only based upon the results obtained using pharmacological interventions or indirect measurement of NO metabolisms (11, 14, 17, 27, 32, 35) . In addition, oxidative stress or lipid peroxidation has been reported to be involved in the development of atherosclerosis or thrombosis in hHcys, but little is known about the direct effects of Hcys on the production of reactive oxygen species in the intact endothelium (7, 8 In an additional group of rats, the aorta below the left renal artery was isolated and cannulated. After ligating the aorta at a site above the right renal artery, the kidneys were flushed with 10 ml ice-cold PSS following 60 ml air perfusion to remove the endothelium of the renal arteries. Then, the small renal arteries were dissected to measure agonist-induced NO production. These experiments were performed to confirm that NO was derived from the renal arterial endothelium [1, 19] . Statistics. Data are presented as mean ± SEM. The significance of differences in mean values between and within multiple groups were examined using an analysis of variance for repeated measures followed by a Duncan's multiple range test (Sigmastat). P<0.05
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was considered statistically significant.
RESULTS
Blockade of A23187-induced increase in endothelial NO fluorescence by L-NAME. As shown in Fig. 1A , addition of A23187 (2 µM) into the bath solution produced a marked increase in endothelial green NO fluorescence of the small renal arteries. In the presence of L-NAME, A23187-induced increase in NO green fluorescence was significantly attenuated, suggesting that L-NAME is capable of blocking the A23187-induced increase in NO within the intact endothelium of these freshly isolated renal arteries. production in the renal endothelium, but L-cysteine and GSH at the same concentration had no effect on O 2 .-production in these endothelial cells.
DISCUSSION
In the present study, we directly measured intracellular [NO] in the endothelium of the small renal arteries using DAF-2 fluorescence microscopic imaging analysis and monitored the production of NO within renal arterial endothelial cells in response to endothelium-dependent vasodilators, A23187 and bradykinin. In the intact endothelium of freshly-dissected small renal arteries loaded with DAF-2DA, both A23187 and bradykinin were found to stimulate the production of a strong green fluorescence, which represented increases in [NO] within endothelial cells (19) . The NOS inhibitor, L-NAME or the removal of the endothelium completely blocked A23187-and bradykinin-induced increase in [NO] in this preparation, suggesting that detected NO increases in response to both compounds are derived from the endothelium of these arteries.
Last decade, numerous studies have been performed to examine the regulation of NO production in the arterial endothelium and to explore the mechanisms of NOmediated endothelial dysfunction under different pathological conditions, such as hypertension, atherosclerosis, and myocardial ischemia and reperfusion (16, 37) . In the kidney, endothelium-derived NO has been found to play a critical role in the regulation of renal vascular tone and renal function (11, 41, 42) . However, most of those studies used pharmacological interventions to block or enhance NOS activity and then observed the changes in endothelial function such as endothelium-dependent vasodilation or endothelium-dependent alterations of blood perfusion in different vascular beds (16, 37).
There were few studies to address these issues by directly measuring endothelial NO. The present study used DAF-2DA, a novel cell permeable fluorescent indicator of NO and dynamically monitored the NO response in the intact endothelium of freshly dissected small renal arteries to endothelium-dependent vasodilators. This preparation provides a valuable model for studying the regulation of NO production and its physiological or pathological significance in renal circulation. 
